Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 21, 2026
TickeronGET DAILY SIGNALS
Molina Healthcare (MOH) Posts Q3 Beat but Shares Fall -5.5% on Margin Concerns

Molina Healthcare (MOH) Posts Q3 Beat but Shares Fall -5.5% on Margin Concerns

Key Takeaways

  • Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share, topping the FactSet consensus estimate of $0.79 by $0.10.
  • Total revenue came in at $11.08 billion, above the $10.86 billion consensus, though it declined 3.4% from $11.48 billion a year earlier.
  • GAAP net income fell 52% to $38 million, or $0.73 per share, from $79 million, or $1.51 per share, in the prior-year quarter, reflecting higher medical costs.
  • Management reaffirmed full-year 2026 adjusted EPS guidance of $5.25 and held premium revenue guidance at roughly $42 billion.
  • Total membership continued to shrink, driven by a steep decline in Marketplace enrollment, while the consolidated medical care ratio rose year over year.
  • The stock slipped roughly 5.5% after the release as investors weighed the headline beat against ongoing margin pressure.

Why This Quarter Matters

Molina Healthcare is one of the largest Medicaid-focused managed care organizations in the United States, which makes its quarterly results a closely watched barometer for government-sponsored health insurance. The company has spent the past several quarters contending with falling enrollment following the end of pandemic-era Medicaid protections, alongside elevated medical costs. This quarter was important because investors were looking for evidence that Molina's margin challenges are stabilizing and that its planned 2027 recovery remains on track. With the stock trading well above its 52-week low, the market had already begun pricing in a rebound, making the details of this report especially significant for the outlook. To get a broader view of how MOH stacks up against peers, I also checked this using Tickeron’s AI Screener.

The Quarter in Detail

Molina Healthcare reported third-quarter 2026 adjusted earnings of $0.89 per share, exceeding the FactSet consensus estimate of $0.79 per share. Total revenue of $11.08 billion also topped the $10.86 billion consensus. On a GAAP (generally accepted accounting principles) basis, however, net income fell 52% to $38 million, or $0.73 per share, compared with $79 million, or $1.51 per share, in the same period last year. Adjusted net income was $46 million.

The decline reflects a meaningful contraction in the business. Premium revenue of approximately $10.46 billion fell about 4% year over year as membership shrank. The consolidated MCR (medical care ratio, which measures medical costs as a percentage of premium revenue) rose year over year, and the company's Medicaid segment, its largest, also saw its MCR climb. Total ending membership declined to roughly 4.86 million from about 5.63 million a year earlier, with Marketplace enrollment falling sharply from approximately 713,000 to 267,000 members.

Despite the pressures, management reaffirmed full-year 2026 adjusted EPS guidance of $5.25 and left premium revenue guidance unchanged at approximately $42 billion. The quarter also included a non-cash impairment charge tied to the company's decision to exit its Medicare Advantage Prescription Drug (MAPD) product in 2027, part of a strategic shift to focus on dual-eligible members.

Market Reaction and Investor Sentiment

The market's initial response was cautious. Despite the double beat on earnings and revenue, shares of MOH declined about 5.5% in after-hours trading following the release, suggesting that investors were more focused on the underlying margin squeeze than on the headline figures. A 52% drop in GAAP net income and a rising consolidated MCR signaled that the company is still absorbing higher medical costs and shrinking membership.

The muted reaction echoed the prior quarter, when an earnings beat was similarly overshadowed by concerns about the operating picture. Heading into this report, analyst sentiment had turned more cautious, with consensus estimates revised downward in the weeks before the release. The stock's decline after the print indicates that the market remains skeptical until there is clearer evidence that Medicaid margins are turning.

Forward Outlook and Key Factors to Monitor

Looking ahead, the central question is whether Molina Healthcare can deliver the margin recovery that the market has already begun to price in. CEO Joseph Zubretsky indicated that the company is seeing an apparent plateauing of medical cost trend and that the strength of 2027 rate updates suggests Molina may be "likely observing the beginning of the turn in Medicaid margins." That commentary will be a key benchmark for investors in the quarters ahead.

Membership trends will remain critical. Medicaid enrollment has been declining industry-wide, and investors should watch whether that contraction stabilizes ahead of new work requirements taking effect in 2027. The company's strategic exit from its Medicare Advantage Prescription Drug product is also worth monitoring, as it reflects a deliberate narrowing of focus toward dual-eligible members.

Finally, cost management will be the defining factor. With the consolidated MCR still elevated, any further uptick in medical costs could quickly erode the thin margin between premiums and claims. Reaffirmed full-year guidance of $5.25 in adjusted EPS provides a floor for near-term expectations, but the trajectory of 2027 rates and medical cost trends will ultimately determine whether the anticipated recovery materializes. Investors will be watching upcoming earnings for confirmation that margins are improving rather than merely stabilizing.

AI Tools in My Research Process

In my own work, I regularly use Tickeron’s AI Screener to quickly filter for stocks showing similar technical patterns or fundamental shifts in the managed care space. It helps surface comparable names and monitor signals without spending hours on manual screens, which keeps my analysis focused on the key drivers like medical cost trends and enrollment changes.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: MOH

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for MOH turns negative, indicating new downward trend

MOH saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 63 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 76%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for MOH moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 34 similar instances where the indicator moved out of overbought territory. In 24 of the 34 cases, the stock moved lower in the following days. This puts the odds of a move lower at 71%.

The Moving Average Convergence Divergence Histogram (MACD) for MOH turned negative on November 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 31 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 67%.

MOH moved below its 50-day moving average on November 19, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MOH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 65%.

MOH broke above its upper Bollinger Band on November 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

The 10-day moving average for MOH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 62%.

Following a +1.70% 3-day Advance, the price is estimated to grow further. Considering data from situations where MOH advanced for three days, in 215 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.

The Aroon Indicator entered an Uptrend today. In 158 of 222 cases where MOH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 71%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. MOH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 90 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 99 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.616) is normal, around the industry mean (3.520). MOH's P/E Ratio (1306.188) is considerably higher than the industry average of (126.353). Projected Growth (PEG Ratio) (0.880) is also within normal values, averaging (0.786). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.233) is also within normal values, averaging (0.569).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MOH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
1-on-1 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of health care services to persons eligible for Medicaid

Industry ManagedHealthCare

Industry
Managed Health Care
Address
200 Oceangate
Phone
+1 562 435-3666
Employees
19000
Web
https://www.molinahealthcare.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.